Ruben Mesa: Most active combination for MF to date

Ruben Mesa shared on LinkedIn:

“Honored to be a Co-Investigator of important Pelabresib plus RUX 1L vs RUX Phase III trial presented as dual abstracts at EHA2024 by Raajit Rampal demonstrating impact of PELA/RUX on fibrosis, erythroid progenitors, VAF, splenomegaly and most symptoms. Most active combination for MF to date!”

Source: Ruben Mesa/LinkedIn